These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
631 related articles for article (PubMed ID: 32022370)
1. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Morse JS; Lalonde T; Xu S; Liu WR Chembiochem; 2020 Mar; 21(5):730-738. PubMed ID: 32022370 [TBL] [Abstract][Full Text] [Related]
2. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Morse JS; Lalonde T; Xu S; Liu WR ChemRxiv; 2020 Jan; ():. PubMed ID: 32511285 [TBL] [Abstract][Full Text] [Related]
3. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Goyal B; Goyal D ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186 [TBL] [Abstract][Full Text] [Related]
4. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov. Zhang H; Saravanan KM; Yang Y; Hossain MT; Li J; Ren X; Pan Y; Wei Y Interdiscip Sci; 2020 Sep; 12(3):368-376. PubMed ID: 32488835 [TBL] [Abstract][Full Text] [Related]
5. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Sternberg A; McKee DL; Naujokat C Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679 [TBL] [Abstract][Full Text] [Related]
6. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884 [TBL] [Abstract][Full Text] [Related]
7. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237 [TBL] [Abstract][Full Text] [Related]
9. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548 [TBL] [Abstract][Full Text] [Related]
10. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
11. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 RNA polymerase as target for antiviral therapy. Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758 [TBL] [Abstract][Full Text] [Related]
14. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Martorana A; Gentile C; Lauria A Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574 [TBL] [Abstract][Full Text] [Related]
16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
17. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Li JY; You Z; Wang Q; Zhou ZJ; Qiu Y; Luo R; Ge XY Microbes Infect; 2020 Mar; 22(2):80-85. PubMed ID: 32087334 [TBL] [Abstract][Full Text] [Related]
18. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2. Patil AM; Göthert JR; Khairnar V Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930 [TBL] [Abstract][Full Text] [Related]
19. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108 [TBL] [Abstract][Full Text] [Related]